BioNTech (NASDAQ:BNTX) Earns Buy Rating from Berenberg Bank

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reissued by research analysts at Berenberg Bank in a note issued to investors on Friday,MarketScreener reports.

BNTX has been the subject of a number of other reports. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the stock from $115.00 to $142.00 in a research report on Friday, January 16th. Bank of America decreased their price target on shares of BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, October 22nd. TD Cowen restated a “hold” rating on shares of BioNTech in a research note on Monday, November 3rd. HC Wainwright restated a “buy” rating and set a $140.00 price target on shares of BioNTech in a research report on Thursday, December 11th. Finally, Jefferies Financial Group restated a “buy” rating and set a $151.00 price target on shares of BioNTech in a research report on Wednesday, December 3rd. Eleven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.03.

BioNTech Trading Down 2.1%

Shares of BNTX opened at $115.98 on Friday. The firm has a fifty day simple moving average of $99.39 and a two-hundred day simple moving average of $103.68. The stock has a market capitalization of $26.12 billion, a P/E ratio of -44.10 and a beta of 1.40. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. BioNTech has a twelve month low of $81.20 and a twelve month high of $126.77.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The firm had revenue of $1.78 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter in the previous year, the firm earned $0.81 earnings per share. BioNTech’s revenue was up 22.0% on a year-over-year basis. On average, research analysts anticipate that BioNTech will post -3.88 EPS for the current year.

Institutional Trading of BioNTech

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Dodge & Cox lifted its stake in BioNTech by 315.7% in the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after acquiring an additional 2,769,654 shares in the last quarter. Bank of America Corp DE boosted its holdings in BioNTech by 344.4% during the third quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock worth $56,544,000 after purchasing an additional 444,332 shares during the last quarter. Bank of New York Mellon Corp grew its position in BioNTech by 58.8% in the second quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock valued at $118,045,000 after purchasing an additional 410,351 shares in the last quarter. SG Americas Securities LLC increased its stake in BioNTech by 1,664.6% in the 4th quarter. SG Americas Securities LLC now owns 365,333 shares of the company’s stock valued at $34,780,000 after buying an additional 344,630 shares during the last quarter. Finally, Aberdeen Group plc lifted its position in BioNTech by 87.2% during the 2nd quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock worth $76,864,000 after buying an additional 336,260 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.